OSTEOSARCOMA RECURRENT
Clinical trials for OSTEOSARCOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OSTEOSARCOMA RECURRENT trials appear
Sign up with your email to follow new studies for OSTEOSARCOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat bone cancer? experimental drug combo enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called tegavivint combined with the chemotherapy gemcitabine in people whose osteosarcoma (a type of bone cancer) has returned or not responded to standard treatments. The main goal is to find the safest dose of tegavivint when given with g…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 06:45 UTC
-
New drug cocktail aims to stall childhood cancers
Disease control Recruiting nowThis study tests a new oral drug, AMXT 1501, combined with another drug called DFMO for children and young adults (up to age 21) with certain cancers like neuroblastoma, brain tumors, and sarcomas. The first part finds the safest dose, and the second part checks if the combo help…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Can a simple drug keep sarcoma from coming back?
Disease control Recruiting nowThis study tests whether a drug called DFMO can help prevent cancer from returning in children and young adults with relapsed Ewing sarcoma or osteosarcoma who have finished all other treatments and show no signs of cancer. About 15 participants will take DFMO for up to two years…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Promising combo therapy for childhood cancers enters human trials
Disease control Recruiting nowThis study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated May 18, 2026 12:00 UTC